A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

May 31, 2030

Study Completion Date

December 31, 2032

Conditions

Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic

Interventions

DRUG

Pirtobrutinib

Administered orally

DRUG

Idelalisib

Administered orally

Trial Locations (1)

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY